

Breast cancer update: Sentinel node biopsy guidelines encourage 'less is more' approach

December 12 2016



New recommendations from breast cancer experts on sentinel lymph node biopsy reinforce the most recent "less-is-more" guidelines for early-stage disease. But according to Dr. Gary Lyman, a Fred Hutch researcher who helped create the guidelines, many surgeons still perform full lymph node dissection. Credit: Fred Hutch News Service



New recommendations from breast cancer experts on sentinel lymph node biopsy reinforce the most recent "less-is-more" guidelines for earlystage disease. But a Fred Hutch researcher who helped create the guidelines said many surgeons still perform full lymph node dissection routinely.

"The new guidelines, first established in 2014, seem to have been embraced within academic centers and larger hospitals and cancer centers, but compliance is still quite variable elsewhere," said Dr. Gary Lyman, first author of the new set of recommendations, published in the Dec. 12 issue of the *Journal of Clinical Oncology*.

"In smaller hospitals, particularly in rural areas, many women are still being told they need a full axillary dissection. There are economic issues, geographic issues and education issues for both clinicians and patients," said Lyman, a Fred Hutch researcher, breast cancer oncologist and codirector of HICOR.

Research by Lyman and others led to the dramatic change in recommendations over the past decade.

Now surgeons are advised to forego routine axillary lymph node dissection in most women with no evidence of cancer on <u>sentinel node</u>



biopsy or if cancer is found in only one to two sentinel nodes. As a result, the majority of women receiving lumpectomy and whole breast radiation can also forego a full lymph node dissection. This is important because axillary lymph node dissection can have a dramatic effect on patients' quality of life, leading to lymphedema, infections, reduced range of motion and other painful and costly side effects.

"There are cautions. The sentinel <u>node biopsy</u> has to be well-conducted, the tumor should not be greater than 5 centimeters in size, and there should be no other major risk factors. However, approximately two thirds of women meet these criteria," Lyman said. "Full removal is always an option, and some women want to have all of the lymph nodes taken out. But given the down side of the full axillary dissection in terms of quality of life and possible complications, many women who have a lower risk say, 'I want to avoid those problems.'"

Sentinel node biopsies are done on <u>early-stage breast cancer</u> patients to stage their cancer and determine if it has infiltrated the lymph node system, a common signal of cancer spread.

Lyman is a major policymaker for ASCO, the American Society of Clinical Oncology. He is also a thought leader in the field of value-based cancer care and precision oncology. Working with many other colleagues, this longtime researcher helped pioneer <u>sentinel lymph node</u> biopsy in <u>breast cancer patients</u> 20 years ago and has been instrumental in shaping policy for <u>breast cancer</u> treatment and surgery ever since.

More information: *Journal of Clinical Oncology*, "Sentinel Lymph Node Biopsy for Patients with Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2016" Dec. 12, 2016



Provided by Fred Hutchinson Cancer Research Center

Citation: Breast cancer update: Sentinel node biopsy guidelines encourage 'less is more' approach (2016, December 12) retrieved 6 May 2024 from https://medicalxpress.com/news/2016-12-breast-cancer-sentinel-node-biopsy.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.